Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
October 27th, 2020
We describe a systematic workflow to investigate TGF-β signaling and TGF-β-induced EMT by studying the protein and gene expression involved in this signaling pathway. The methods include Western blotting, a luciferase reporter assay, qPCR, and immunofluorescence staining.
TGF-beta is a main driver of epithelial-to-mesenchymal transition, in short EMT, which can occur both in normal and in cancer cells. The methods that are described in our protocol allow researchers to measure the impact of modulators on both TGF-beta SMAD signaling and TGF-beta-induced EMT. The untransformed NMuMG cells, which were established from a mouse mammary gland, is a frequently used model system for TGF-beta-induced EMT.
TGF-beta provokes in these cells, these NMuMG cells a very strong EMT response. A similar response can also be seen in breast cancer cells where it contributes to cancer progression. The combined staining of epithelial micro E-cadherin and organization of filamentous-actin helps to validate and better visualize the morphological changes that occur during epithelial-to-mesenchymal transition.
The acquisition of a mesenchymal phenotype by cancer cells has been linked to an increased ability of cells to migrate, to invade, and to metastasize, as well as to chemotherapy resistance. This method may provide important insights into cancer progression, but also into other processes such as tissue fibrosis. While attempting this protocol, keep in mind that cell density should be well-controlled.
High density of the cells makes epithelial-to-mesenchymal transition difficult. With this visual demonstration, researchers will get a good grasp on how to perform TGF-beta signaling and TGF-beta-induced EMT experiments. To perform indirect immunofluorescent staining of E-cadherin, begin by placing sterile 18 millimeter square glass coverslips in six-well plates, one coverslip per well.
Seed 100, 000 NMuMG cells with two milliliters of complete DMEM into each well and allow the cells to adhere overnight. Non-transformed NMuMG cells are frequently used as a model system to investigate TGF-beta-induced EMT. On the next day, gently move the coverslips with adherent cells to a new six-well plate and add two milliliters of culture medium to the wells.
Treat the cells with ligand buffer as a control or five nanograms per milliliter of TGF-beta for two days. The added ligand buffer should be the same volume as the added TGF-beta. After the treatment, remove the culture medium and gently wash the cells twice with one milliliter of pre-warmed PBS.
Fix the cells by adding one milliliter of 4%paraformaldehyde and incubating for 30 minutes at room temperature, then gently wash the cells twice with one milliliter of PBS. Permeabilize the fixed cells with 0.1%Triton X-100 for 10 minutes at room temperature and wash the cells twice with PBS. Block the non-specific protein binding to cells with 5%BSA in PBS for one hour at room temperature, then repeat the washes with PBS.
Add the primary antibody against E-cadherin to the top of each coverslip and incubate for one hour at room temperature. Remove the primary antibody and wash each coverslip with PBS three times. Add the Alexa Fluor 555 secondary antibody and the Alexa Fluor 488 phalloidin to the top of each coverslip.
Then cover with aluminum foil and incubate for one hour at room temperature. Remove the secondary antibody and wash the coverslip three times with PBS. Mount the coverslip with the cells facing downward onto glass slides using mounting medium with DAPI and store the mounted slides in a box at four degrees Celsius protected from light.
Observe the staining with SP8 confocal microscopy. In the MCF10A-Ras cell line, the phosphorylation of SMAD2 significantly increased in response to TGF-beta stimulation, while the expression of total SMAD2 and 3 was not affected. TGF-beta also markedly induced the luciferase reporter in the MCF10A-Ras cell line compared to non-treated cells.
Well-characterized direct transcriptional gene targets of TGF-beta, including SMAD7 and SERPINE1, were highly expressed in TGF-beta-treated MCF10A-Ras breast cells. NMuMG epithelial cells treated with TGF-beta changed from a classic epithelial morphology to a spindle-shaped mesenchymal-like morphology. Consistent with the morphological changes, TGF-beta treatment led to an increase in the protein expression of mesenchymal markers.
In contrast, E-cadherin, an epithelial marker, was down-regulated after two days of TGF-beta treatment. Quantitative real-time polymerase PCR was used to investigate the gene expression of EMT markers after TGF-beta stimulation. CDH1 was significantly decreased while mesenchymal markers were increased.
Upon TGF-beta stimulation, NMuMG cells expressed less E-cadherin than the cells in the control group. Moreover, the cells formed more actin stress fibers in the presence of TGF-beta. Treatment with GW788388 inhibited TGF-beta-induced SMAD2 phosphorylation in a dose-dependent manner.
Additionally, the TGF-beta-mediated phosphorylation of SMAD2 was blocked by SB-431542 treatment. Both SB-431542 and GW788388 significantly inhibited the TGF-beta-induced nuclear translocation and accumulation of SMAD2 and 3 in NMuMG cells. Following this procedure, immunofluorescent staining of other epithelial-to-mesenchymal macroproteins can be performed by changing the specific primary and secondary antibodies to investigate the expression level and the localization of these proteins within the cell.
Overview
This article presents a systematic workflow for investigating TGF-β signaling and TGF-β-induced epithelial-to-mesenchymal transition (EMT). The methods employed include Western blotting, luciferase reporter assays, qPCR, and immunofluorescence staining to analyze protein and gene expression.
Key Study Components
Area of Science
- Cell Biology
- Signal Transduction
- Cancer Research
Background
- TGF-β is a key regulator of EMT, influencing both normal and cancerous cells.
- The NMuMG cell line is a common model for studying TGF-β-induced EMT.
- EMT is associated with increased cell migration, invasion, and metastasis.
- Understanding TGF-β signaling can provide insights into cancer progression and tissue fibrosis.
Purpose of Study
- To elucidate the mechanisms of TGF-β signaling and its role in EMT.
- To assess the effects of different modulators on TGF-β signaling pathways.
- To provide a detailed protocol for researchers to replicate these experiments.
Methods Used
- Western blotting to analyze protein expression.
- Luciferase reporter assays to measure TGF-β signaling activity.
- Quantitative PCR (qPCR) for gene expression analysis.
- Immunofluorescence staining to visualize morphological changes and protein localization.
Main Results
- TGF-β treatment induced a significant EMT response in NMuMG cells.
- Down-regulation of E-cadherin and up-regulation of mesenchymal markers were observed.
- Inhibition of SMAD2 phosphorylation was achieved with specific inhibitors.
- Quantitative PCR confirmed changes in gene expression consistent with EMT.
Conclusions
- The study provides a comprehensive protocol for investigating TGF-β signaling.
- Results highlight the importance of TGF-β in EMT and cancer progression.
- This workflow can be adapted for further studies on EMT and related processes.
Frequently Asked Questions
Executive Industry Relevance
Understanding TGF-β signaling and its role in epithelial-to-mesenchymal transition (EMT) is critical for de-risking breast cancer target validation and identifying mechanistically grounded therapeutic opportunities. This protocol enables quantitative assessment of pathway modulation, supporting predictive confidence in early discovery by linking molecular readouts to phenotypic EMT outcomes. The approach provides a reusable framework for evaluating compound effects on invasion-related biology, informing portfolio triage and mechanistic risk assessment in oncology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of TGF-β receptor kinase activity through SMAD2 phosphorylation measurement, supporting target hypothesis testing.
- Operational Value: Provides a standardized readout for pathway inhibition using small molecule inhibitors like GW788388 and SB431542.
- Scientific Value: Measures transcriptional output via SERPINE1 (PAI-1) expression and luciferase reporter activity, connecting signaling to functional gene regulation.
- Operational Value: Facilitates dose-response analysis of modulator effects on EMT marker shifts, supporting target engagement validation.
Screening & Assay Development
- Scientific Value: Delivers quantitative, multiparametric readouts including protein localization (E-cadherin), actin reorganization, and mesenchymal marker expression for assay robustness.
- Operational Value: Establishes a reproducible immunofluorescence-based platform for screening compounds that block TGF-β-induced EMT in epithelial models.
- Scientific Value: Supports biomarker-aligned assay design by tracking CDH1 downregulation and mesenchymal marker upregulation as coordinated EMT indicators.
- Operational Value: Enables adaptation across models (e.g., MCF10A-RAS, NMuMG, Py2T) for cross-system validation of anti-EMT therapeutics.
Translational & Preclinical Research
- Scientific Value: Links TGF-β signaling to functional EMT phenotypes associated with invasion, migration, and therapy resistance in breast cancer models.
- Operational Value: Provides a preclinical-continuous workflow from signaling inhibition to phenotypic reversal, supporting translational biomarker alignment.
- Scientific Value: Enables assessment of mesenchymal-to-epithelial transdifferentiation (e.g., Py2T to adipocytes) as a measure of pathway reversibility and therapeutic impact.
- Operational Value: Supports risk-adjusted decision-making by connecting target modulation to downstream biological consequences in disease-relevant systems.
Pipeline & Workflow Integration
The method integrates into the discovery continuum by enabling target validation in early biology, supporting assay development for screening campaigns, and informing preclinical progression through mechanistic de-risking of EMT-driven phenotypes.
- Discovery Biology: Supports hypothesis testing of TGF-β’s role in EMT by measuring SMAD2/3 phosphorylation, nuclear translocation, and transcriptional activity.
- Screening: Delivers assay-ready, quantitative outputs (e.g., qPCR, immunofluorescence, Western blot) for evaluating compound effects on signaling and phenotypic change.
- Analytics: Generates normalized, comparable datasets across conditions (ligand, inhibitor, control) to enable data-driven target prioritization.
- Translational Research: Connects pathway inhibition to EMT marker reversal and morphological normalization, supporting biomarker-aligned advancement criteria.
- Enterprise Reuse: Establishes a modular, adaptable platform applicable across epithelial and cancer cell lines for sustained use in target and pathway validation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by linking target inhibition to suppression of EMT hallmarks, reducing mechanistic ambiguity in oncology target validation.
- Operational Value: Promotes standardization through defined cell seeding, treatment timing, fixation, and staining protocols, enhancing reproducibility across sites.
- Strategic Value: Improves go/no-go decisions by providing early evidence of target-mediated effects on invasion-related biology, reducing late-stage failure risk.
- Portfolio Impact: Enables risk-adjusted advancement by validating target engagement and phenotypic response in parallel, supporting efficient capital allocation.
Implementation Considerations
- Requires expertise in cell culture, immunofluorescence microscopy, and quantitative protein/nucleic acid analysis.
- Dependent on access to Western blotting, qPCR, luciferase assay, and confocal microscopy instrumentation.
- Necessitates standardization of cell density and TGF-β dosing to ensure consistent EMT induction across experiments.
- Involves optimization of antibody concentrations and blocking conditions to minimize nonspecific signal in immunofluorescence.
- Limited by the need for careful titration of inhibitors (e.g., GW788388, SB431542) to avoid off-target cytotoxicity at high doses.
